Latest News about Robyn Karnauskas
Recent news which mentions Robyn Karnauskas
Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4
February 05, 2019
Tickers
GILD
From Benzinga
Gilead Sciences Outlook Brightens; Citi Upgrades
January 30, 2018
From Benzinga
Wall Street Reacts To Celgene's Reported Interest In Juno
January 17, 2018
From Benzinga
Citi Downgrades Regeneron, Citing 'Underappreciated' Risk
December 01, 2017
From Benzinga
What To Do With Celgene Now With Major Catalysts Gone
October 20, 2017
From Benzinga
Bluebird News A Positive For Juno, Kite Pharma
December 01, 2016
From Benzinga
Citi Starts Calithera Biosciences At Sell On Cash Burn And Lack Of Near-Term Catalysts
October 25, 2016
From Benzinga
Citi Launches Positive Coverage On Five Prime Therapeutics
October 25, 2016
From Benzinga
Citi Sees 26% Upside In TESARO On The Strength Of Trial Data
October 10, 2016
From Benzinga
Lingo Failure Leads Citi To Downgrade Biogen
June 08, 2016
From Benzinga
Has A Biotech Recovery Started Yet?
May 17, 2016
From Benzinga
Citi: Buy Celgene, Gilead, Biogen And Regeneron As Biotechs Recover
February 25, 2016
From Benzinga
From Benzinga
Wall Street Mixed On Biogen Before Earnings
July 23, 2015
From Benzinga
Deutsche Bank Bullish On Biogen: New Data Doesn't Change Probability Of Success For Alzheimer's
July 22, 2015
Tickers
BIIB
From Benzinga
BioMarin's Results Are In: What Do They Mean?
June 18, 2015
From Benzinga
Gilead Alert: What Deutsche Bank Is Saying
April 06, 2015
From Benzinga
Why BioMarin Pharmaceutical Is Surging
March 27, 2015
From Benzinga
Analysts Mixed On Premium For Pharmacyclics
March 05, 2015
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.